Changes in the Care Activity in Addiction Centers with Dual Pathology Patients During the COVID-19 Pandemic

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 Jul 27

PMID 35893432

Authors

Cinta Mancheno-Velasco

Daniel Dacosta-Sanchez

Andrea Blanc-Molina

Marta Narvaez-Camargo

Oscar Martin Lozano-Rojas

Affiliations

Soon will be listed here.

Abstract

Background: Health care provision during the COVID-19 pandemic and confinement has led to significant changes in the activity of addiction centers. These changes in healthcare activity may have had a greater impact on patients with dual pathology. The aim of this study is to compare the treatment indicators of patients with dual pathology in addiction centers during the pre-confinement, confinement, and post-confinement periods.

Methods: A retrospective observational study was conducted for the period between 1 February 2019 and 30 June 2021. A total of 2785 patients treated in specialized addiction services were divided into three periods according to their time of admission: pre-confinement, confinement, and post-confinement.

Results: During the pre-pandemic period, the addiction centers attended to an average of 121.3 (SD = 23.58) patients, decreasing to 53 patients during confinement (SD = 19.47), and 80.69 during the post-confinement period (SD = 15.33). The number of appointments scheduled monthly for each patient decreased during the confinement period, although this number increased after confinement. There was a reduction in the number of toxicological tests carried out both during and after confinement (except for alcohol).

Conclusions: The results show a reduction in the number of patients seen and the care activity delivered to dual diagnosis patients. These results, which were caused by the COVID-preventive measures, may affect the progress and recovery of dual patients. A greater investment is needed to bring the care activity up to the standards of the years prior to confinement.

Citing Articles

Access and use of general and mental health services before and during the COVID-19 pandemic: a systematic review and meta-analysis.

Sculco C, Bano B, Prina E, Tedeschi F, Bartucz M, Barbui C BMJ Open. 2025; 15(3):e091342.

PMID: 40074252 PMC: 11904334. DOI: 10.1136/bmjopen-2024-091342.

How Has the COVID-19 Pandemic Impacted Addiction Services? A Study of the Different Periods of the Pandemic and Patient Treatment Follow-up Over 1 Year.

Narvaez-Camargo M, Mancheno-Velasco C, Diaz-Batanero C, Fernandez-Calderon F, Lozano O Subst Use. 2025; 19():29768357241306717.

PMID: 39802982 PMC: 11724415. DOI: 10.1177/29768357241306717.

Recent Advances in Dual Disorders (Addiction and Other Mental Disorders).

Torrens M, Adan A J Clin Med. 2023; 12(9).

PMID: 37176755 PMC: 10179482. DOI: 10.3390/jcm12093315.

References

Mark T, Gibbons B, Barnosky A, Padwa H, Joshi V . Changes in Admissions to Specialty Addiction Treatment Facilities in California During the COVID-19 Pandemic. JAMA Netw Open. 2021; 4(7):e2117029. PMC: 8280956. DOI: 10.1001/jamanetworkopen.2021.17029. View

Tirado Munoz J, Farre A, Mestre-Pinto J, Szerman N, Torrens M . Dual diagnosis in Depression: treatment recommendations. Adicciones. 2017; 30(1):66-76. DOI: 10.20882/adicciones.868. View

Dubey M, Ghosh R, Chatterjee S, Biswas P, Chatterjee S, Dubey S . COVID-19 and addiction. Diabetes Metab Syndr. 2020; 14(5):817-823. PMC: 7282772. DOI: 10.1016/j.dsx.2020.06.008. View

Manthey J, Kilian C, Carr S, Bartak M, Bloomfield K, Braddick F . Use of alcohol, tobacco, cannabis, and other substances during the first wave of the SARS-CoV-2 pandemic in Europe: a survey on 36,000 European substance users. Subst Abuse Treat Prev Policy. 2021; 16(1):36. PMC: 8072737. DOI: 10.1186/s13011-021-00373-y. View

Griffiths M, Mamun M . COVID-19 suicidal behavior among couples and suicide pacts: Case study evidence from press reports. Psychiatry Res. 2020; 289:113105. PMC: 7229970. DOI: 10.1016/j.psychres.2020.113105. View

Ries R . Serial, parallel, and integrated models of dual-diagnosis treatment. J Health Care Poor Underserved. 1992; 3(1):173-80. DOI: 10.1353/hpu.2010.0283. View

Pollard M, Tucker J, Green Jr H . Changes in Adult Alcohol Use and Consequences During the COVID-19 Pandemic in the US. JAMA Netw Open. 2020; 3(9):e2022942. PMC: 7525354. DOI: 10.1001/jamanetworkopen.2020.22942. View

Bonati M, Campi R, Segre G . Psychological impact of the quarantine during the COVID-19 pandemic on the general European adult population: a systematic review of the evidence. Epidemiol Psychiatr Sci. 2022; 31:e27. PMC: 9069583. DOI: 10.1017/S2045796022000051. View

Allen B, El Shahawy O, Rogers E, Hochman S, Khan M, Krawczyk N . Association of substance use disorders and drug overdose with adverse COVID-19 outcomes in New York City: January-October 2020. J Public Health (Oxf). 2020; 43(3):462-465. PMC: 7799011. DOI: 10.1093/pubmed/fdaa241. View

10.

Mancheno J, Navas-Leon S, Fernandez-Calderon F, Gutierrez M, Sanchez-Garcia M, Diaz-Batanero C . Coordinated treatment between addiction and mental health services vs. uncoordinated treatment for patients with dual diagnosis: higher dropout rates but lower impairement of functional disability. Actas Esp Psiquiatr. 2021; 49(2):71-80. View

11.

Huskamp H, Busch A, Uscher-Pines L, Barnett M, Riedel L, Mehrotra A . Treatment of Opioid Use Disorder Among Commercially Insured Patients in the Context of the COVID-19 Pandemic. JAMA. 2020; 324(23):2440-2442. PMC: 7739126. DOI: 10.1001/jama.2020.21512. View

12.

Preti E, Di Pierro R, Fanti E, Madeddu F, Calati R . Personality Disorders in Time of Pandemic. Curr Psychiatry Rep. 2020; 22(12):80. PMC: 7652908. DOI: 10.1007/s11920-020-01204-w. View

13.

MacKillop J, Cooper A, Costello J . National Retail Sales of Alcohol and Cannabis During the COVID-19 Pandemic in Canada. JAMA Netw Open. 2021; 4(11):e2133076. PMC: 8569488. DOI: 10.1001/jamanetworkopen.2021.33076. View

14.

Garcia-Rivera B, Garcia-Alcaraz J, Mendoza-Martinez I, Olguin-Tiznado J, Garcia-Alcaraz P, Aranibar M . Influence of COVID-19 Pandemic Uncertainty in Negative Emotional States and Resilience as Mediators against Suicide Ideation, Drug Addiction and Alcoholism. Int J Environ Res Public Health. 2021; 18(24). PMC: 8701151. DOI: 10.3390/ijerph182412891. View

15.

Finlay I, Gilmore I . Covid-19 and alcohol-a dangerous cocktail. BMJ. 2020; 369:m1987. DOI: 10.1136/bmj.m1987. View

16.

Aguilar L, Vicente-Hernandez B, Remon-Gallo D, Garcia-Ullan L, Valriberas-Herrero I, Macia-Casas A . A real-world ten-week follow-up of the COVID outbreak in an outpatient drug clinic in Salamanca (Spain). J Subst Abuse Treat. 2021; 125:108303. PMC: 8065063. DOI: 10.1016/j.jsat.2021.108303. View

17.

Dacosta-Sanchez D, Diaz-Batanero C, Fernandez-Calderon F, Lozano O . Impact of Cluster B Personality Disorders in Drugs Therapeutic Community Treatment Outcomes: A Study Based on Real World Data. J Clin Med. 2021; 10(12). PMC: 8230360. DOI: 10.3390/jcm10122572. View

18.

Daigre C, Grau-Lopez L, Palma-Alvarez R, Perea-Ortueta M, Sorribes-Puertas M, Serrano-Perez P . A Multicenter Study on the Impact of Gender, Age, and Dual Diagnosis on Substance Consumption and Mental Health Status in Outpatients Treated for Substance Use Disorders During COVID-19 Lockdown. J Dual Diagn. 2022; 18(2):71-80. DOI: 10.1080/15504263.2022.2051110. View

19.

Gili A, Bacci M, Aroni K, Nicoletti A, Gambelunghe A, Mercurio I . Changes in Drug Use Patterns during the COVID-19 Pandemic in Italy: Monitoring a Vulnerable Group by Hair Analysis. Int J Environ Res Public Health. 2021; 18(4). PMC: 7922660. DOI: 10.3390/ijerph18041967. View

20.

Slavova S, Rock P, Bush H, Quesinberry D, Walsh S . Signal of increased opioid overdose during COVID-19 from emergency medical services data. Drug Alcohol Depend. 2020; 214:108176. PMC: 7351024. DOI: 10.1016/j.drugalcdep.2020.108176. View